

# Measuring the medium-term impact of school-based interventions as girls transition into adulthood

<b>Submission date</b> 19/12/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 19/12/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/05/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Studies have been conducted to evaluate the benefits of keeping girls in school on their sexual and reproductive health and productivity. These suggested that most improvements occur if girls complete secondary education, with additional gains in child marriage and pregnancy for each extra year of school attended. They also noted that girls completing secondary school earn up to 5-fold more, have a one-third reduction in total fertility, increased contraception use by a third, and a ~25% reduction in child stunting compared with girls with no education. However, few follow-up studies have examined these effects and whether they have any longer-term effect as AGYW reach adulthood. There are conflicting results on lasting effects of school-based interventions when girls are followed up for about 2 years after finishing school, with one study showing a continued reduction in pregnancy rates, while another shows no difference in HIV rates compared with girls who had not received any school-based intervention. Our UK funded trial among 4,137 Kenyan secondary schoolgirls, providing cash, a menstrual cup, or both, examined if interventions reduce school dropout, HIV, HSV-2, and SRH harms compared with girls not provided interventions. As this trial has finished, we aim to follow-up prior trial participants to evaluate if previous school interventions have any effects on their health and social equity as they transition to adulthood and measure the cost benefits of the prior trial interventions.

### Who can participate?

Girls who took part in the prior trial can participate.

### What does the study involve?

The study will follow-up girls between July 2022 and October 2025, with two surveys with additional data captured through health facility record reviews. We will use a socio-behavioural survey questionnaire, ask some questions on their mental health, and offer HIV/HSV-2 testing to participants who previously tested negative, through individual follow-up of consenting girls (at home or in select community locations of their choice). We will examine if girls who previously received interventions have better decision making on health access, better SRH and mental health, if they have had less children, and if their children have been healthy, compared with girls

who received no interventions in the past trial. We will also conduct interviews and have discussion groups with girls, and with stakeholders to understand whether they perceived the past school interventions were of value.

What are the possible benefits and risks of participating?

Participants will receive items in the CCG2 Members Pack. Participants knowledge of their health status (HIV, HSV-2) will contribute to their improved health and social outcomes. Participants are thought likely to benefit from improving their self-esteem and autonomy by contributing to the study. Risks involve the taking of blood for HIV and HSV-2 tests, upset over some questions e.g., relating to personal history or violence, breaches of confidentiality. These will be mitigated where possible with uptake of safeguarding mechanisms, training, availability of counselling, signposting to services, and safe keeping of all documentation.

Where is the study run from?

Kenya Medical Research Institute, Kisumu, Kenya

When is the study starting and how long is it expected to run for?

April 2022 to October 2025

Who is funding the study?

Medical Research Council, United Kingdom

Who is the main contact?

Prof Penelope Phillips-Howard, Liverpool School of Tropical Medicine  
penelope.phillips-howard@lstmed.ac.uk

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Penelope Phillips-Howard

### ORCID ID

<https://orcid.org/0000-0003-1018-116X>

### Contact details

Department of Clinical Sciences  
Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool  
United Kingdom  
L3 5QA  
+44 7985431005  
Penelope.Phillips-Howard@lstmed.ac.uk

## Additional identifiers

Protocol serial number

## Study information

### Scientific Title

Cups or Cash for Girls Follow-up Study

### Acronym

CCG2

### Study objectives

As the cohort follow-up study is exploratory in nature it does not have a pre-specified hypothesis.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 15/09/2022, Liverpool School of Tropical Medicine Research and Ethics Committee (Pembroke Place, Liverpool, L3 5QA, UK; lstmrec@lstmed.ac.uk; +44 151 702 9396) Ref: #22-030

### Study design

Single site longitudinal study following up a cohort of participants in a prior school-based trial

### Primary study design

Observational

### Study type(s)

Other

### Health condition(s) or problem(s) studied

Potential reduction in sexual and reproductive health and mental health harms as schoolgirls transition out of school into adulthood

### Interventions

Prior trial interventions:

1. One reusable menstrual cup
2. Cash transfer pocket money (~\$15 per school term)
3. Menstrual cup plus cash transfer
4. Control; cup provided at end of prior trial

The prior trial is registered at <https://clinicaltrials.gov/ct2/show/NCT03051789>

The present trial is a follow up survey of participants from the prior trial.

### Intervention Type

Mixed

### Primary outcome(s)

No one primary outcome, as this is exploratory comprising health and social equity (see below for all outcomes)

## **Key secondary outcome(s))**

### **1. Health**

- 1.1. Number of participant deaths measured using mobile alert system and survey
- 1.2. Reported PHQ-9-A score measured using questionnaires at survey
- 1.3. Number of and incidence of intimate partner violence measured using questionnaires at survey
- 1.4. Other mental health scores (GAD, PCL) measured using questionnaires at survey
- 1.5. Number and prevalence of cigarette smokers measured using questionnaires at survey
- 1.6. Number and prevalence of alcohol drinkers measured using questionnaires at survey
- 1.7. BMI score and weight status (underweight[<18.5], healthy[18.5-24.9], overweight[25-29.9], obese[30>]) measured using anthropometric measurement at survey
- 1.8. Number and prevalence of clinically obese measured using anthropometric measurement at survey
- 1.9. Number and prevalence of anaemia measured using hospital records

### **2. Sexual health:**

- 2.1. Number of and incidence of HIV measured using questionnaires at survey
- 2.2. Number of and incidence of HSV-2 measured using questionnaires at survey
- 2.3. Age sexual debut measured using questionnaires at survey
- 2.4. Number of sex partners measured using questionnaires at survey
- 2.5. Age at time of first born measured using questionnaires at survey
- 2.6. Age at marriage measured using questionnaires at survey

### **3. Reproductive health:**

- 3.1. Number of and incidence of pregnancies measured using questionnaires at survey
- 3.2. Number and incidence of live births measured using questionnaires at survey, mobile alert system, hospital records
- 3.3. Number and incidence of stillbirths measured using questionnaires at survey, mobile alert system, hospital records
- 3.4. Number and incidence of abortions measured using questionnaires at survey, mobile alert system, hospital records
- 3.5. Number and incidence of neonatal, post-natal, infant deaths measured using questionnaires at survey, mobile alert system, hospital records
- 3.6. Number and incidence of low birth weight (LBW) babies measured using hospital records
- 3.7. Number and incidence of infant / child stunting measured using hospital records

### **4. Health seeking, health care**

- 4.1. Number of ANC visits during pregnancy using questionnaires at survey, hospital records
- 4.2. Place of delivery of offspring using questionnaires at survey, mobile alert system, hospital records
- 4.3. Number and prevalence of offspring with infant vaccinations given using questionnaires at survey, mobile alert system, hospital records
- 4.4. Resorts to health care if sick (Index depicting healthcare-seeking behaviour) using questionnaires at survey, mobile alert system, hospital records

### **5. Covid-19**

- 5.1. Number and prevalence having covid-19 vaccine using questionnaires at survey
- 5.2. Number and incidence of covid infections using questionnaires at survey
- 5.3. Number and proportion who have been vaccinated using questionnaires at survey
- 5.4. Number and prevalence of AGYW reporting covid-related changes in behaviours using questionnaires at survey
- 5.5. Number and prevalence of AGYW reporting covid-related changes in income and employment using questionnaires at survey

### **6. Prior intervention prospective measures and social equity**

- 6.1. Number and prevalence of menstrual cup use using questionnaires at survey

- 6.2. Number and prevalence of prior dropouts who returned to school using questionnaires at survey
- 6.3. Attainment (KCSE grade) using school records
- 6.4. Participant educational level reached (incomplete secondary, completed secondary, tertiary) using questionnaires at survey
- 6.5. Partner or husbands' education level (grade reached) using questionnaires at survey
- 6.6. Employed (occupation; part-time, full time) using questionnaires at survey
- 6.7. Annualised own / family income using questionnaires at survey

**Completion date**

31/10/2025

## **Eligibility**

**Key inclusion criteria**

1. Adolescent girls and young women who were enrolled as schoolgirls in the prior CCG trial
2. Stakeholders who live and/or work in the area of the prior CCG trial

**Participant type(s)**

Mixed

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Adolescent girls and young women not participating in the prior trial
2. Adolescent girls and young women in prior trial who refuse consent
3. Stakeholders who do not have daughters, or who do not work with adolescent girls and young women

**Date of first enrolment**

09/02/2023

**Date of final enrolment**

31/12/2024

## **Locations**

**Countries of recruitment**

Kenya

**Study participating centre**

**Kenya Medical Research Institute**  
Centre for Global Health Research  
Kisian Campus  
Kisumu  
Kenya  
4100

## Sponsor information

### Organisation

Liverpool School of Tropical Medicine

### ROR

<https://ror.org/03svjbs84>

## Funder(s)

### Funder type

Research council

### Funder Name

Medical Research Council

### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

Individual participant data (IPD) sharing plan

Data for this study will be available upon request, after obtaining written approval for the proposed analysis from the KEMRI SERU. Their application forms and guidelines can be accessed at <https://www.kemri.org/seru-overview>. To request these data, please contact the KEMRI SERU at [seru@kemri.org](mailto:seru@kemri.org).

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol file</a>	version 0.5	10/07/2022	19/12/2022	No	No